Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;386(4):331-8.
doi: 10.1007/s00210-012-0820-5. Epub 2012 Dec 19.

Inhibitory effect of anethole in nonimmune acute inflammation

Affiliations

Inhibitory effect of anethole in nonimmune acute inflammation

Talita Perdigão Domiciano et al. Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr.

Abstract

Anethole [1-methoxy-4-(1-propenyl)benzene] occurs naturally as a major component of the essential oil of star anise (Illicium verum Hook.f., family Illiciaceae), comprising more than 90 % of its volatile components. Studies showed that this substance has antioxidant, antibacterial, antifungal, and anesthetic properties. In this study, the anti-inflammatory properties of anethole in animal models of nonimmune acute inflammation such as croton oil-induced ear edema and carrageenan-induced pleurisy were investigated. The investigated parameters were edema formation, leukocyte migration, and inflammatory mediators involved. Oral administration of anethole at a dose of 250 and 500 mg/kg reduced both the volume of pleural exudates and the number of migrated leukocytes. Levels of nitric oxide (NO) and prostaglandins (PGE2) in the inflammatory exudate were reduced by treatment with anethole, but levels of tumor necrosis factor-α and interleukin-1β were not significantly altered. In ear edema, the oral treatment with anethole inhibited the formation of exudate and the activity of myeloperoxidase, but not after topical administration. These results suggest that the anethole may be effective in controlling some nonimmune acute inflammation-related disease, probably by an inhibitory action on production and/or release of PGE2 and NO.

PubMed Disclaimer

References

    1. J Invest Dermatol. 1982 Mar;78(3):206-9 - PubMed
    1. Toxicol In Vitro. 2006 Oct;20(7):1098-105 - PubMed
    1. Methods Enzymol. 1996;268:237-46 - PubMed
    1. Mediators Inflamm. 2010;2010:682879 - PubMed
    1. Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5954-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources